+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), Disease Type, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 129 Pages
  • July 2022
  • Region: United States
  • 360iResearch™
  • ID: 5122506
UP TO OFF until Dec 31st 2022
The United States Childhood Absence Epilepsy Treatment Market size was estimated at USD 42.08 million in 2021, USD 47.41 million in 2022, and is projected to grow at a CAGR 9.14% to reach USD 71.15 million by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug, the market was studied across Lamotrigine, Phase 2 Drugs, and Valproate.
  • Based on Disease Type, the market was studied across Atypical Absence Seizures and Typical Absence Seizures.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Childhood Absence Epilepsy Treatment market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Childhood Absence Epilepsy Treatment Market, including Abbott Laboratories Inc., AbbVie Inc., Ada Health GmbH, Cavion, Inc., CENTOGENE N.V., Clarivate PLC, Dr. Reddy’s Laboratories Inc., GlaxoSmithKline plc, Insys Therapeutics, Merck & Co., Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Xenon Pharmaceuticals Inc..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Childhood Absence Epilepsy Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Childhood Absence Epilepsy Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Childhood Absence Epilepsy Treatment Market?
4. What is the competitive strategic window for opportunities in the United States Childhood Absence Epilepsy Treatment Market?
5. What are the technology trends and regulatory frameworks in the United States Childhood Absence Epilepsy Treatment Market?
6. What is the market share of the leading vendors in the United States Childhood Absence Epilepsy Treatment Market?
7. What modes and strategic moves are considered suitable for entering the United States Childhood Absence Epilepsy Treatment Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Childhood Absence Epilepsy Treatment Market, by Drug
6.1. Introduction
6.2. Lamotrigine
6.3. Phase 2 Drugs
6.4. Valproate
7. Childhood Absence Epilepsy Treatment Market, by Disease Type
7.1. Introduction
7.2. Atypical Absence Seizures
7.3. Typical Absence Seizures
8. California Childhood Absence Epilepsy Treatment Market9. Florida Childhood Absence Epilepsy Treatment Market10. Illinois Childhood Absence Epilepsy Treatment Market11. New York Childhood Absence Epilepsy Treatment Market12. Ohio Childhood Absence Epilepsy Treatment Market13. Pennsylvania Childhood Absence Epilepsy Treatment Market14. Texas Childhood Absence Epilepsy Treatment Market
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbott Laboratories Inc.
16.2. AbbVie Inc.
16.3. Ada Health GmbH
16.4. Cavion, Inc.
16.5. CENTOGENE N.V.
16.6. Clarivate PLC
16.7. Dr. Reddy’s Laboratories Inc.
16.8. GlaxoSmithKline plc
16.9. Insys Therapeutics
16.10. Merck & Co., Inc.
16.11. Pfizer Inc.
16.12. Sanofi SA
16.13. Teva Pharmaceutical Industries Ltd.
16.14. Xenon Pharmaceuticals Inc.
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2021 VS 2027 (USD MILLION)
FIGURE 3. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 4. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2027
FIGURE 7. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET DYNAMICS
FIGURE 8. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2021 VS 2027 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2027
FIGURE 11. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, 2019-2027 (USD MILLION)
FIGURE 12. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 13. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, 2019-2027 (USD MILLION)
FIGURE 14. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, 2019-2027 (USD MILLION)
FIGURE 16. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 18. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2027
FIGURE 20. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, 2019-2027 (USD MILLION)
FIGURE 21. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, 2019-2027 (USD MILLION)
FIGURE 23. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 24. CALIFORNIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 25. FLORIDA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 26. ILLINOIS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 27. NEW YORK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 28. OHIO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 29. PENNSYLVANIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 30. TEXAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
FIGURE 31. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 32. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 33. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 4. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2019-2027 (USD MILLION)
TABLE 5. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 6. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY STATE, 2019-2027 (USD MILLION)
TABLE 7. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PHASE 2 DRUGS, BY STATE, 2019-2027 (USD MILLION)
TABLE 8. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY STATE, 2019-2027 (USD MILLION)
TABLE 9. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 10. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ATYPICAL ABSENCE SEIZURES, BY STATE, 2019-2027 (USD MILLION)
TABLE 11. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TYPICAL ABSENCE SEIZURES, BY STATE, 2019-2027 (USD MILLION)
TABLE 12. CALIFORNIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 13. CALIFORNIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 14. CALIFORNIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 15. FLORIDA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 16. FLORIDA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 17. FLORIDA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 18. ILLINOIS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 19. ILLINOIS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 20. ILLINOIS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 21. NEW YORK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 22. NEW YORK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 23. NEW YORK CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 24. OHIO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 25. OHIO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 26. OHIO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 27. PENNSYLVANIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 28. PENNSYLVANIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 29. PENNSYLVANIA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 30. TEXAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2019-2027 (USD MILLION)
TABLE 31. TEXAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG, 2019-2027 (USD MILLION)
TABLE 32. TEXAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD MILLION)
TABLE 33. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 34. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 35. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 36. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RANKING
TABLE 37. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2021
TABLE 38. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET MERGER & ACQUISITION
TABLE 39. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 40. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 41. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET INVESTMENT & FUNDING
TABLE 42. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 43. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • Ada Health GmbH
  • Cavion, Inc.
  • CENTOGENE N.V.
  • Clarivate PLC
  • Dr. Reddy’s Laboratories Inc.
  • GlaxoSmithKline plc
  • Insys Therapeutics
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Xenon Pharmaceuticals Inc.

Methodology

Loading
LOADING...